-+ 0.00%
-+ 0.00%
-+ 0.00%

Sionna Therapeutics Presents Plans for Phase 2 Trial of Cystic Fibrosis Drug Combination

PUBT·11/10/2026 12:18:09
Listen to the news
Sionna Therapeutics Presents Plans for Phase 2 Trial of Cystic Fibrosis Drug Combination
  • Sionna Therapeutics expects to initiate its AscenSION CF Phase 2 proof-of-concept trial of SION-451 + SION-2222 in the first quarter of 2027.
  • The open-label trial will evaluate the two-drug regimen in cystic fibrosis patients switching from Trikafta for 28 days.
  • Phase 1 testing met safety and tolerability objectives, with drug exposure exceeding targets in the selected dose range.
  • Cash totaled approximately $250 million at third-quarter 2026, providing runway into the second half of 2029.
  • Investment is prioritized toward SION-451 + SION-2222, with cash expected to fund AscenSION CF and subsequent development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.